Health
FDA revokes EUA for monoclonal antibody therapy bamlanivimab to treat patients with COVID-19 – News-Medical.Net
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab,…
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment…
-
Business20 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News23 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses
-
Noosa News22 hours agoNick Cave and The Bad Seeds Are Bringing Their ‘Wild God’ Tour to Australia and New Zealand in 2026
-
Business23 hours agoThese small cap ASX shares could rise 10% to 40%